{"filing":{"accession_number":"0001193805-26-000645","cik":"0001280776","ticker":"IMUX","company_name":"IMMUNIC, INC.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"e665479_8k-immunic.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/e665479_8k-immunic.htm"},"events":[{"id":10117,"run_id":8867,"accession_number":"0001193805-26-000645","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Michael W. Bonney was appointed as Chair of the Board effective May 16, 2026. Mr. Bonney brings extensive executive and board leadership experience from prior CEO roles at Cubist Pharmaceuticals and Kaleido Biosciences, and this senior governance appointment is material to investors assessing the company's strategic direction.","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-05-19","form":"8-K","submitted_at":null,"items":[{"id":214,"accession_number":"0001193805-26-000645","item_number":"5.02","item_title":"Departure of Directors or Principal Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael W. Bonney was appointed as Chair of the Board effective May 16, 2026, a principal officer position. The disclosure details his extensive executive and board leadership experience across multiple biotechnology companies, including prior CEO roles at Cubist Pharmaceuticals and Kaleido Biosciences. This appointment of a senior board leadership position is material to investors assessing the company's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:22:20.885165+00:00","company_name":"","ticker":null,"filing_date":""},{"id":215,"accession_number":"0001193805-26-000645","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Mr. Bonney as Chair of the Board, announced via press release on May 19, 2026. This is a material executive appointment to a senior governance role. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment that would affect a reasonable investor's assessment of the company's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:22:20.885165+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":214,"accession_number":"0001193805-26-000645","item_number":"5.02","item_title":"Departure of Directors or Principal Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael W. Bonney was appointed as Chair of the Board effective May 16, 2026, a principal officer position. The disclosure details his extensive executive and board leadership experience across multiple biotechnology companies, including prior CEO roles at Cubist Pharmaceuticals and Kaleido Biosciences. This appointment of a senior board leadership position is material to investors assessing the company's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:22:20.885165+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-05-19"},{"id":215,"accession_number":"0001193805-26-000645","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Mr. Bonney as Chair of the Board, announced via press release on May 19, 2026. This is a material executive appointment to a senior governance role. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment that would affect a reasonable investor's assessment of the company's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:22:20.885165+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-05-19"}]}